Kimberly Stegmaier

List of Publications by Year
in descending order

108	13,302	61984 43	33894 99
papers	citations	h-index	g-index

116	116	116	26068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	27.8	4,761
2	Computational correction of copy number effect improves specificity of CRISPRâ€“Cas9 essentiality screens in cancer cells. Nature Genetics, 2017, 49, 1779-1784.	21.4	1,436
3	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 2013, 3, 308-323.	9.4	549
4	Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discovery, 2016, 6, 914-929.	9.4	485
5	The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery, 2014, 4, 1326-1341.	9.4	415
6	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	21.4	333
7	Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific Data, 2014, 1, 140035.	5.3	328
8	Gene expressionâ€“based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nature Genetics, 2004, 36, 257-263.	21.4	276
9	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
10	EWSâ€“FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature, 2018, 555, 387-391.	27.8	222
11	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics, 2018, 50, 1240-1246.	21.4	199
12	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. JAMA Oncology, 2016, 2, 608.	7.1	172
13	Proteomic and Genetic Approaches Identify Syk as an AML Target. Cancer Cell, 2009, 16, 281-294.	16.8	140
14	Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer. Cancer Cell, 2013, 23, 390-405.	16.8	130
15	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications, 2020, 11, 4687.	12.8	129
16	Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma. PLoS Medicine, 2007, 4, e122.	8.4	129
17	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 226-242.	16.8	126
18	Targeting MTHFD2 in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 1285-1306.	8.5	118

#	Article	IF	Citations
19	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 2014, 46, 618-623.	21.4	117
20	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. Journal of Clinical Investigation, 2017, 128, 446-462.	8.2	117
21	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	16.8	116
22	The intersection of genetic and chemical genomic screens identifies GSK-3Î± as a target in human acute myeloid leukemia. Journal of Clinical Investigation, 2012, 122, 935-947.	8.2	96
23	Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation. Chemistry and Biology, 2013, 20, 713-725.	6.0	89
24	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Cancer Cell, 2017, 31, 549-562.e11.	16.8	89
25	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2017, 23, 1012-1024.	7.0	88
26	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Childrenâ€™s Oncology Group. British Journal of Cancer, 2018, 119, 615-621.	6.4	83
27	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine, 2017, 23, 301-313.	30.7	79
28	A first-generation pediatric cancer dependency map. Nature Genetics, 2021, 53, 529-538.	21.4	76
29	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget, 2014, 5, 8737-8749.	1.8	72
30	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell, 2019, 35, 664-676.e7.	16.8	70
31	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	13.2	70
32	Exploiting an Asp-Glu â€œswitchâ€• in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, 2018, 10, .	12.4	69
33	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 1343-1357.	7.0	69
34	Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Scientific Reports, 2020, 10, 5324.	3.3	69
35	Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget, 2015, 6, 30178-30193.	1.8	68
36	EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discovery, 2022, 12, 730-751.	9.4	64

#	Article	IF	Citations
37	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell, 2018, 34, 922-938.e7.	16.8	63
38	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	1.8	55
39	Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chemical Biology, 2016, 11, 1952-1963.	3.4	55
40	Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. Journal of Experimental Medicine, 2018, 215, 2137-2155.	8.5	55
41	Targeting chromatin complexes in fusion protein-driven malignancies. Nature Reviews Cancer, 2019, 19, 255-269.	28.4	55
42	Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo. Blood, 2020, 135, 56-70.	1.4	49
43	TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. Cancer Cell, 2021, 39, 1262-1278.e7.	16.8	49
44	New Approaches to Target T-ALL. Frontiers in Oncology, 2014, 4, 170.	2.8	48
45	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2017, 7, 1336-1353.	9.4	48
46	Phase I trial of the mTOR inhibitor everolimus in combination with multiâ€agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27062.	1.5	48
47	TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports, 2018, 25, 1255-1267.e5.	6.4	46
48	Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications, 2016, 7, 11987.	12.8	45
49	Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. Bioorganic and Medicinal Chemistry, 2017, 25, 6479-6485.	3.0	43
50	MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Research, 2019, 79, 2404-2414.	0.9	43
51	The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell, 2022, 40, 301-317.e12.	16.8	43
52	Comparative proteomics reveals a diagnostic signature for pulmonary headâ€andâ€neck cancerÂmetastasis. EMBO Molecular Medicine, 2018, 10, .	6.9	41
53	Ushering in the next generation of precision trials for pediatric cancer. Science, 2019, 363, 1175-1181.	12.6	41
54	EWSâ€“FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Research, 2019, 47, 9619-9636.	14.5	35

#	Article	IF	Citations
55	Bepridil exhibits antiâ€leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. International Journal of Cancer, 2018, 143, 958-970.	5.1	32
56	Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations. Journal of Medicinal Chemistry, 2019, 62, 2428-2446.	6.4	32
57	An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discovery, 2022, 12, 432-449.	9.4	32
58	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. Journal of Experimental Medicine, 2018, 215, 197-216.	8.5	30
59	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Science Translational Medicine, 2021, 13, .	12.4	29
60	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Reports, 2020, 33, 108493.	6.4	28
61	RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress. Genes and Development, 2021, 35, 556-572.	5.9	28
62	Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discovery, 2020, 10, 214-231.	9.4	27
63	Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. Cell Chemical Biology, 2020, 27, 678-697.e13.	5.2	27
64	Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry, 2021, 221, 113481.	5.5	27
65	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood, 2022, 139, 538-553.	1.4	27
66	Evaluation of Improved Glycogen Synthase Kinase-3Î± Inhibitors in Models of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2015, 58, 8907-8919.	6.4	25
67	Biology and Therapy of Dominant Fusion Oncoproteins Involving Transcription Factor and Chromatin Regulators in Sarcomas. Annual Review of Cancer Biology, 2019, 3, 299-321.	4.5	25
68	Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Reports, 2019, 28, 2331-2344.e8.	6.4	24
69	Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia, 2022, 36, 1585-1595.	7.2	24
70	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 430-434.	0.8	23
71	Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia, 2022, 36, 348-360.	7.2	23
72	Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nature Cancer, 2022, 3, 976-993.	13.2	23

#	Article	IF	Citations
73	Targeted therapy for fusion-driven high-risk acute leukemia. Blood, 2018, 132, 1241-1247.	1.4	22
74	Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. Cancer Discovery, 2021, 11, 2282-2299.	9.4	21
75	Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget, 2015, 6, 25575-25587.	1.8	20
76	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 2017, 8, 52026-52044.	1.8	19
77	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 8.	17.0	16
78	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery, 2021, 11, 1424-1439.	9.4	16
79	IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nature Cancer, 2022, 3, 595-613.	13.2	16
80	Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Reports, 2018, 24, 3393-3403.e5.	6.4	15
81	A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes and Development, 2022, 36, 368-389.	5.9	14
82	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Cancer Discovery, 2020, 10, 1894-1911.	9.4	13
83	Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. Cancer Research, 2021, 81, 3971-3984.	0.9	11
84	Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. Leukemia, 2019, 33, 800-804.	7.2	10
85	Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells. JCI Insight, 2019, 4, .	5.0	10
86	Genomic approaches in acute leukemia. Best Practice and Research in Clinical Haematology, 2006, 19, 263-268.	1.7	8
87	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia, 2021, 23, 624-633.	5.3	8
88	Transcriptional Plasticity Drives Leukemia Immune Escape. Blood Cancer Discovery, 2022, 3, 394-409.	5.0	8
89	Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics. Cancer Genetics, 2019, 237, 69-77.	0.4	6
90	Targeting DUBs to degrade oncogenic proteins. British Journal of Cancer, 2020, 122, 1121-1123.	6.4	6

#	Article	IF	Citations
91	KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia. Oncotarget, 2018, 9, 29665-29679.	1.8	6
92	Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia. Cell Death and Disease, 2022, 13, .	6.3	6
93	Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Advances, 2020, 4, 1265-1269.	5.2	5
94	Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma. Cancer Cell, 2017, 32, 271-273.	16.8	3
95	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. Blood, 2018, 132, 261-261.	1.4	3
96	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Blood, 2019, 134, 877-877.	1.4	1
97	Modulating AML1-ETO with Signature-Based Small Molecule Library Screening.. Blood, 2006, 108, 729-729.	1.4	1
98	Targeting Folate Metabolism In Acute Myelogenous Leukemia. Blood, 2013, 122, 3798-3798.	1.4	1
99	Targeting Csnk1a1 in leukemia. Journal of Experimental Medicine, 2014, 211, 594-594.	8.5	0
100	Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL. Blood, 2008, 112, 200-200.	1.4	0
101	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3Î± (GSK-3Î±) as a Modulator of Differentiation In Acute Myeloid Leukemia. Blood, 2010, 116, 1000-1000.	1.4	0
102	Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies. Blood, 2011, 118, 555-555.	1.4	0
103	In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. Blood, 2011, 118, 758-758.	1.4	0
104	Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML. Blood, 2015, 126, 2472-2472.	1.4	0
105	Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. Blood, 2016, 128, 889-889.	1.4	0
106	Transcriptional Immunoediting of AML Cells after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 647-647.	1.4	0
107	Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL. Blood, 2021, 138, 705-705.	1.4	0
108	Abstract 3889: Identification of ADRN-specific, MES-specific, and pan-subtype therapeutic targets in neuroblastoma. Cancer Research, 2022, 82, 3889-3889.	0.9	0